Company profile
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
- CEO
- Mr. Chris Kim J.D., L.L.M.
- Headquarters
- Cerritos, CA, United States
- Employees
- 1
- IPO date
- May 1, 2025
- Sector
- Healthcare
- Industry
- Biotechnology